Axia Pharmaceutical Recalls Compounded Testosterone Cypionate and Progesterone Vials
Axia Pharmaceutical is recalling 120 vials of compounded Testosterone Cypionate and Progesterone due to CGMP deviations. The product was distributed to one customer in California.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a situation where use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences. The source cites CGMP deviations without reporting specific injuries or illnesses, aligning with a Moderate severity rating for a voluntary, limited-distribution drug recall.
Plain-English summary
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical is voluntarily recalling 120 vials of Testosterone Cypionate + Progesterone, 200 mg/2.5 mg/mL, 10 mL amber glass vials. The recall was initiated on July 12, 2017, and is classified as Class II by the FDA. The reason for the recall is cited as CGMP (Current Good Manufacturing Practice) deviations.
The affected product is identified by Lot # 03022017+44906 with a beyond-use date of August 29, 2017. The recall status is currently terminated. The distribution was limited to one customer located in California.
Consumers and healthcare providers who possess this specific lot of compounded medication should stop using it and contact their healthcare provider or the recalling firm for instructions on return or disposal. The recall was initiated by the firm and notified via letter.
The recalled product
- Product
- Testosterone Cypionate + Progesterone, 200 mg/ 2.5 mg/mL ,10 mL amber glass vials, Rx Only, Compounded by AXIA Pharmaceutical, Los Angeles, CA 90025
- Category
- Drug — Compounded Injectable
- Hazard
- Affected units
- 120
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 03022017+44906
- BUD 08/29/17
Distribution
Distributed in 1 state:
Related recalls
Same manufacturer · Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
See all →- Severe
- SevereAxia Pharmaceutical Recalls Selenium Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- Severe
- SevereAxia Pharmaceutical Recalls Hydroxyprogesterone Caproate Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- SevereAxia Pharmaceutical Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19